• Explore /
  • Poster
  • / Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC).

Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Maria C. Riesco Martinez

Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, ON, Canada

Maria C. Riesco Martinez , Scott R. Berry , Yoo-Joung Ko , Nicole Mittmann , Kelly Lien , Shazia Hassan , Angie Giotis , Kelvin K. Chan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research

Track

Health Services Research

Sub Track

Cost

Citation

J Clin Oncol 31, 2013 (suppl; abstr 6552)

DOI

10.1200/jco.2013.31.15_suppl.6552

Abstract #

6552

Poster Bd #

12H

Abstract Disclosures

Similar Posters

First Author: David Chan

First Author: B. Chibaudel

First Author: Hideaki Bando

First Author: Shu Okamura